tiprankstipranks
X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials
Company Announcements

X4 Pharmaceuticals Advances CN Treatment with Mavorixafor Trials

Don't Miss our Black Friday Offers:

X4 Pharmaceuticals (XFOR) has issued an announcement.

X4 Pharmaceuticals has shared promising interim results from their Phase 2 clinical trial of mavorixafor in treating chronic neutropenia (CN), revealing that the drug was well tolerated and effectively increased absolute neutrophil counts. This has led to the initiation of a pivotal Phase 3 trial aimed at further evaluating mavorixafor’s safety and efficacy. The positive outcomes from the Phase 2 trial, which involved both monotherapy and combination therapy with G-CSF, are significant for patients with CN, who currently have limited treatment options.

For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyX4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskX4 Pharmaceuticals Reports Positive Trial Results and Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App